Maxona Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Maxona Pharmaceuticals is a private, clinical-stage company developing non-opioid, non-NSAID pain therapies. Its lead asset, MAX-001, is an optimized formulation of a molecule with a long history of safe use outside the U.S., currently advancing through clinical trials with Phase II completion expected in 2025. The company is led by a seasoned team with expertise in CNS disorders, drug development, and commercialization, targeting the massive and urgent unmet need in the pain management market.

Pain ManagementNeurology

Technology Platform

Optimized formulation and development of established non-opioid, non-NSAID molecules with prior clinical history, focusing on pharmacokinetic refinement and new dosage forms.

Opportunities

The urgent, massive need for non-addictive pain therapies creates a receptive market and regulatory environment.

MAX-001's long history of safe use internationally could accelerate physician adoption and payer coverage if approved.

Success could lead to expansion into additional chronic pain indications and formulations.

Risk Factors

Clinical failure in Phase II trials is the primary risk, as efficacy in new U.S.

trials is unproven.

The company is pre-revenue and dependent on external financing.

The non-opioid pain market is highly competitive with many novel approaches in development.

Competitive Landscape

The non-opioid analgesic space is crowded and competitive, featuring large pharma and numerous biotechs pursuing novel targets (e.g., nerve growth factor, sodium channels) and repurposed drugs. Maxona's differentiation lies in developing a compound with a decades-long safety record, potentially offering a faster, de-risked path to market compared to novel mechanisms.

More companies in Small Molecule Drugs →More companies in United States →